-
ASCO 2021: Summary Overview and Prospects 14|Special Research Progress of Non-Small Cell Lung Cancer (02)
Time of Update: 2021-06-04
Screening ImmunizationOriginal source: Germline mutations in patients with non-small cell lung cancer.
Real-world data on the results of continuous treatment regimens involving anti-PDx-1 in advanced and metastatic non-small cell lung cancerDoes the order matter?
-
ASCO 2021: Summary Overview and Prospects 20 | Special Research Express on Non-Small Cell Lung Cancer (03)
Time of Update: 2021-06-04
In this retrospective study, the overall survival (OS) and progression-free survival (PFS) of NSCLCBM patients treated with first, second, and third generation ALK inhibitors were investigated .
-
Domestic drug news | The first domestically-made first-line hepatocellular carcinoma targeted drug will soon be approved for marketing, and Cinda Bio’s PD-1 inhibitor is expected to usher in the third indication in China...
Time of Update: 2021-06-04
The results of the National Medical Products Administration (NMPA) drug registration progress query show that Cinda Bio and Eli Lilly and Company jointly developed PD The third indication of the -1 inhibitor Sintilizumab has been "under approval" for the first-line treatment of squamous non-small cell lung cancer (NSCLC).
-
Another predictive marker for immunotherapy is released; HR+ breast cancer prognosis AJCC staging system may be changed|Tumor News
Time of Update: 2021-06-04
New drug: Innovative FGFR inhibitor was approved by FDA accelerated 01ANNALS OF ONCOLOGY: tTMB is a significant and independent predictor outside of PD-L1 status in Ⅲ In the phase KEYNOTE-061 trial (NCT02370498), compared with paclitaxel, pembrolizumab in the second-line treatment of PD-L1 combined positive score (CPS) ≥1 gastric/gastroesophageal junction (GEJ) adenocarcinoma failed to significantly improve overall Lifetime.
-
The first KRAS inhibitor to receive accelerated approval from the US FDA for the treatment of non-small cell lung cancer
Time of Update: 2021-06-04
Pancreatic cancer and colorectal cancerStomach cancerRecently, the US Food and Drug Administration Board approved Lumakras (sotorasib) as a method for the treatment of adult patients with the first non-small cell lung cancer, tumors of these patients have a particular type of genetic mutation, known as KRAS G12C, and received at least once before System treatment.
-
STTT cover highlights: Xiujun Cai's team found that metabolic reprogramming promotes resistance to targeted therapy for liver cancer
Time of Update: 2021-06-04
In this study, the research team found that under the same concentration of sorafenib treatment, the level of ROS in drug-resistant cells was significantly lower than that in wild-type cells, which supports the regulation of intracellular ROS balance involved in the development of sorafenib resistance Conjecture.
-
The effective rate of lung cancer treatment has increased by 2.5 times. How is it done?
Time of Update: 2021-06-04
In 2021, the American Society of Clinical Oncology ASCO reported a study that combined with PD-1 inhibitor pembrolizumab (Drug K) after concurrent radiotherapy and chemotherapy for stage III lung cancer can achieve a treatment response rate of 70%.
-
Progress of bispecific antibodies in the treatment of RRMM | ASCO prospects in 2021
Time of Update: 2021-06-04
According to the standards of the International Myeloma Working Group (IMWG), the overall response rate (ORR) of patients with a dose of ≥215 µg/kg is 75% (n=15/20), including partial response (PR, n=6), very Good partial remission (VGPR, n=3), complete remission (CR, n=1), strict complete remission (sCR, n=5); the median time to remission was 22 days, and 4 cases had previously received targeted Three (75%) patients treated with BCMA achieved remission (VGPR, n=2; sCR, n=1).
-
Nat Com: Improving the body's own immunity can fight cancer
Time of Update: 2021-06-04
In the three-dimensional environment and living tumors, the researchers found that microtubule instability leads to the increase of Rho Rho pathway-dependent cortical contraction, which promotes migration, while the clinically used microtubule stabilization chemotherapy greatly reduces effective migration.
-
J Med Chem: Dual PROTAC is here: Chinese scholars first proposed a new concept of dual-targeted degradation (Dual PROTACs) drug design
Time of Update: 2021-06-04
This research creatively proposes a new concept for the design of dual-targeted degradation drugs (Dual PROTACs), using the existing EGFR inhibitor Gefitinib and PARP inhibitor Olaparib as raw materials to synthesize different link lengths and different E3 ligases (CRBN- and VHL- ) The recruited EGFR and PARP protein dual target degradation chimeric molecules (Dual PROTACss), and successfully degrade both EGFR and PARP proteins in cancer cells at the cellular level.
-
Professor Yuming Zhu: Osimertinib is approved for adjuvant treatment indications, guarding patients' benefits throughout the process
Time of Update: 2021-06-04
S. Food and Drug Administration (FDA) for the adjuvant treatment of early-stage non-small cell lung cancer (NSCLC) patients with EGFR mutations Indications.
Professor Zhu Yuming pointed out: “The clinical use of drugs emphasizes evidence-based medicine evidence, and osimertinib is recommended by NCCN guidelines and approved by NMPA for postoperative adjuvant treatment indications for patients with EGFR mutations.
-
Xuzhou Medical University Song Jun/Wang Renhao discovers new potential therapeutic targets for colorectal cancer
Time of Update: 2021-06-04
On June 1, 2021, Song Jun and Wang Renhao from Xuzhou Medical University published an online report entitled "The circular RNA circSPARC enhances the migration and proliferation of colorectal cancer by regulating the JAK/STAT pathway" in Molecular Cancer (IF=15.
-
ASCO 2021 | Feng Shi Min, "Shuang Ai Combination" multiple research progress announced
Time of Update: 2021-06-04
Including the Zhao Mingfang team of the First Affiliated Hospital of China Medical University on the study design of carrelizumab monotherapy or combined with apatinib for the treatment of PD-L1-positive advanced pulmonary sarcomatoid carcinoma was selected for the poster of this conference, and we look forward to the announcement of follow-up research results 9 .
-
Nature Communications: Not only vaccines, mRNA technology can also treat rare genetic diseases
Time of Update: 2021-06-04
published a research paper titled: mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease in Nature Communications.
-
Gastric Cancer: Efficacy and safety of ramucirumab in the treatment of advanced gastric cancer: a post-marketing observational real-world study from Japan
Time of Update: 2021-06-04
A research team from Japan conducted a post-marketing observational study of ramucirumab, aiming to evaluate the efficacy and safety of ramucirumab as a single agent or combination in the treatment of advanced gastric cancer in the real world.
-
Ann Oncol: Nivolumab (Nivolumab) second-line treatment does not improve the prognosis of small cell lung cancer: from CheckMate 331 clinical study
Time of Update: 2021-06-04
Therefore, the investigators conducted a phase III clinical study CheckMate 331 to evaluate the efficacy and safety of nivolumab compared to second-line chemotherapy in the treatment of SCLC.
-
Br J Cancer: Research on the correlation between physical activity, grip strength, sedentary behavior and the risk of malignant melanoma
Time of Update: 2021-06-04
The researchers aimed to explore the physical activity, grip strength, and sedentary behavior associated with the risk of malignant melanoma, and analyzed prospective cohort study data to explain related confounding factors.
-
JCO: Venetog combined with FLAG-IDA can improve the deep remission rate and transplant success rate of newly diagnosed and relapsed/refractory AML
Time of Update: 2021-06-04
About 60% of newly diagnosed acute myeloid leukemia (ND-AML) patients who have received front-line treatment have achieved complete remission (CR), but about 30%-40% of patients will relapseThis is a phase IB/II clinical trial that evaluated fludarabine, cytarabine, granulocyte colony stimulating factor and idarubicin in combination with the B-cell lymphoma -2 inhibitor Venetog for ND -Safety and effectiveness in patients with AML and R/R-AML.
-
A number of new studies on metformin!
Time of Update: 2021-06-04
In this study, most women with type 2 diabetes took metformin, which may help reduce the risk of estrogen receptor (ER)-positive breast cancer.
Previous studies have shown that inhibiting mTOR with drugs can significantly inhibit the replication of HIV in the cells of patients infected with the virus, thereby reducing chronic inflammation.
-
The whole course of neoadjuvant treatment improves the remission rate and survival rate of patients with rectal cancer
Time of Update: 2021-06-04
The whole course of neoadjuvant treatment can improve the pathological complete remission rate of patients with rectal cancer.
Ilson, MD, PhD and standard treatment In contrast, the whole course of neoadjuvant therapy also improved the patient's 3-year disease-free survival rate.
